BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


SEARCH JOBS

View Clinical Trials from BioPharm Insight


The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.


 Key Statistics


Email: contactus@themedco.com
Ownership: Public

Web Site: The Medicines Company
Employees: 500+
Symbol: MDCO
 





Collaborations

UCB, Inc.  Contract manufacturing of Bivalirudin peptide active ingredient

Alnylam Pharmaceuticals 





 Company News
The Medicines Company (MDCO) Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients 11/17/2014 11:50:11 AM
The Medicines Company (MDCO) To Present New Data On Investigational Lipid-Modifying Agent MDCO-216 And Investigational Antiplatelet Agent Cangrelor At 2014 American Heart Association Annual Scientific Sessions In Chicago 11/14/2014 9:40:57 AM
The Medicines Company (MDCO) To Participate In Credit Suisse Healthcare Conference 11/11/2014 10:39:31 AM
Health Economic Data On The Medicines Company (MDCO)’s Infectious Disease And Cardiology Portfolios To Be Presented At The 17th Annual European Congress Of The International Society For Pharmacoeconomics And Outcomes Research (ISPOR) 11/10/2014 11:42:08 AM
The Medicines Company (MDCO) Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE™ In Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria 11/5/2014 10:33:34 AM
Update to The Medicines Company (MDCO) Investor & Analyst Day On November 5 11/5/2014 9:59:28 AM
The Medicines Company (MDCO) To Webcast Investor & Analyst Day On November 5 10/31/2014 8:55:36 AM
The Medicines Company (MDCO) Announces Presentation Of Investigational Hemostatic Agent RAPLIXA™ (Fibrin Sealant) Phase 3 FINISH-3 Trial Results At The 2014 Clinical Conference Of American College of Surgeons 10/29/2014 10:38:44 AM
Alnylam Pharmaceuticals (ALNY) And The Medicines Company (MDCO) Announce Filing Of A Clinical Trial Application To Initiate A Phase 1 Study For ALN-PCSsc, An Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia 10/28/2014 10:31:11 AM
The Medicines Company (MDCO) Wins Favorable Judgment In Angiomax® (Bivalirudin) Patent Litigation 10/28/2014 10:21:38 AM
12345678910...